van Ballegooijen M - Search Results

1

Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.

de Kok IM, van Ballegooijen M, Habbema JD. de Kok IM, et al. Among authors: van ballegooijen m. J Natl Cancer Inst. 2009 Aug 5;101(15):1083-92. doi: 10.1093/jnci/djp183. Epub 2009 Jul 1. J Natl Cancer Inst. 2009. PMID: 19571256

2

Cost-effectiveness of cervical cancer screening: comparison of screening policies.

van den Akker-van Marle ME, van Ballegooijen M, van Oortmarssen GJ, Boer R, Habbema JD. van den Akker-van Marle ME, et al. Among authors: van oortmarssen gj, van ballegooijen m. J Natl Cancer Inst. 2002 Feb 6;94(3):193-204. doi: 10.1093/jnci/94.3.193. J Natl Cancer Inst. 2002. PMID: 11830609

3

Human papillomavirus testing for triage of women referred because of abnormal smears. a decision analysis considering outcomes and costs.

Meerding WJ, van Ballegooijen M, Burger MP, van den Akker-van Marle ME, Quint WG, Habbema JD. Meerding WJ, et al. Among authors: van den akker van marle me, van ballegooijen m. J Clin Epidemiol. 2002 Oct;55(10):1025-32. doi: 10.1016/s0895-4356(02)00456-0. J Clin Epidemiol. 2002. PMID: 12464379

4

Nonattendance is still the main limitation for the effectiveness of screening for cervical cancer in the Netherlands.

Bos AB, Rebolj M, Habbema JD, van Ballegooijen M. Bos AB, et al. Among authors: van ballegooijen m. Int J Cancer. 2006 Nov 15;119(10):2372-5. doi: 10.1002/ijc.22114. Int J Cancer. 2006. PMID: 16858676

5

Human papillomavirus triage of women with persistent borderline or mildly dyskaryotic smears: Comparison of costs and side effects of three alternative strategies.

Rebolj M, Bais AG, van Ballegooijen M, Boer R, Meerding WJ, Helmerhorst TJ, Habbema JD. Rebolj M, et al. Among authors: van ballegooijen m. Int J Cancer. 2007 Oct 1;121(7):1529-35. doi: 10.1002/ijc.22838. Int J Cancer. 2007. PMID: 17565745

6

Does lowering the screening age for cervical cancer in The Netherlands make sense?

van der Aa MA, de Kok IM, Siesling S, van Ballegooijen M, Coebergh JW. van der Aa MA, et al. Among authors: van ballegooijen m. Int J Cancer. 2008 Sep 15;123(6):1403-6. doi: 10.1002/ijc.23652. Int J Cancer. 2008. PMID: 18566998

7

No increased risk for cervical cancer after a broader definition of a negative Pap smear.

Rebolj M, van Ballegooijen M, van Kemenade F, Looman C, Boer R, Habbema JD. Rebolj M, et al. Among authors: van kemenade f, van ballegooijen m. Int J Cancer. 2008 Dec 1;123(11):2632-5. doi: 10.1002/ijc.23803. Int J Cancer. 2008. PMID: 18767046

8

At what costs will screening with CT colonography be competitive? A cost-effectiveness approach.

Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, Boer R, Wilschut J, Habbema JD. Lansdorp-Vogelaar I, et al. Among authors: van ballegooijen m. Int J Cancer. 2009 Mar 1;124(5):1161-8. doi: 10.1002/ijc.24025. Int J Cancer. 2009. PMID: 19048626 Free PMC article.

9

A novel hypothesis on the sensitivity of the fecal occult blood test: Results of a joint analysis of 3 randomized controlled trials.

Lansdorp-Vogelaar I, van Ballegooijen M, Boer R, Zauber A, Habbema JD. Lansdorp-Vogelaar I, et al. Among authors: van ballegooijen m. Cancer. 2009 Jun 1;115(11):2410-9. doi: 10.1002/cncr.24256. Cancer. 2009. PMID: 19288570 Free PMC article.

10

Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening.

Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, Habbema JD, Kuipers EJ. Lansdorp-Vogelaar I, et al. Among authors: van ballegooijen m. J Natl Cancer Inst. 2009 Oct 21;101(20):1412-22. doi: 10.1093/jnci/djp319. Epub 2009 Sep 24. J Natl Cancer Inst. 2009. PMID: 19779203 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

192 results

Search Page

Filters